Abstract
The kinetics of phenobarbital (PB) were evaluated in six normal subjects and six epileptic patients treated with phenytoin or carbamazepine. Each normal subject received three single doses of PB: PB-sodium 130 mg i.v. (IV), PB sodium 10 mg i.m. (IM), and PB acid 100 mg orally (PO), in random order at least one month apart. After IV PB distributive half-lives were 75 to 126 h, steady state volume of distribution (Vss) was 0.54 +/- 0.03 l/kg, and clearance (CL) was 3.8 +/- 0.77 ml/h/kg. Absolute bioavailability of IM PB was 101 +/- 11%. Peak serum PB concentrations were achieved from 2 to 8 h after IM administration, and from 0.5 to 4 h after PO administration. Epileptic patients exhibited similar PB kinetics: disposition half-lives were 77 to 128 h, Vss 0.61 +/- 0.05 l/kg, and Cl 3.9 +/- 0.76 ml/h/kg. Phenobarbital appears to represent an exception among antiepileptic drugs, in that pharmacokinetic data obtained in normal car reasonably be extrapolated to the epileptic population.
MeSH Terms
Administration, Oral
Adult
Biological Availability
Carbamazepine/pharmacology
Epilepsy/metabolism
Female
Humans
Injections, Intramuscular
Injections, Intravenous
Kinetics
Male
Phenobarbital/metabolism
Phenytoin/pharmacology
Chemicals
Carbamazepine
Phenytoin
Phenobarbital
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Wilensky A J
Friel P N
Levy R H
Comfort C P
Kaluzny S P
References (19)
19 references, click to expand
-
The clinical significance of microsomal enzyme induction in the therapy of epileptic patients.
Ann Clin Res. 1970 Sep;2(3):223-7
PMID: 5473162
-
Plasma concentrations of phenobarbital in the treatment of seizures in newborns.
Acta Paediatr Scand. 1975 May;64(3):514-24
PMID: 1155069
-
Factors influencing plasma phenobarbitone levels in epileptic patients.
Br J Clin Pharmacol. 1977 Oct;4(5):541-7
PMID: 911604
-
Phenobarbital--valporic acid interaction.
Clin Pharmacol Ther. 1980 Apr;27(4):515-21
PMID: 6766833
-
Bioavailability of oral and intramuscular phenobarbital.
J Clin Pharmacol. 1978 Feb-Mar;18(2-3):100-5
PMID: 624773
-
Intravenous phenobarbital therapy in barbiturate and other hypnosedative withdrawal reactions: a kinetic approach.
Clin Pharmacol Ther. 1979 Aug;26(2):256-64
PMID: 455894
-
Disappearance of phenobarbital and diphenylhydantoin from serum of children.
Clin Pharmacol Ther. 1970 Sep-Oct;11(5):674-9
PMID: 5455632
-
The effect of liver disease in man on the disposition of phenobarbital.
J Pharmacol Exp Ther. 1975 Jan;192(1):224-35
PMID: 235636
-
Plasma and cerebrospinal fluid concentrations of phenobarbital in infants given single doses.
Dev Med Child Neurol. 1974 Dec;16(6):781-93
PMID: 4442659
-
Plasma levels and urinary excretion of three barbituric acids after oral administration to man.
Acta Pharmacol Toxicol (Copenh). 1954;10(2):147-65
PMID: 14349708
-
The effect of anticonvulsant drugs which induce liver microsomal enzymes on derived and ingested phenobarbitone levels.
Acta Neurol Scand. 1977 Jul;56(1):1-6
PMID: 878841
-
Clorazepate kinetics in treated epileptics.
Clin Pharmacol Ther. 1978 Jul;24(1):22-30
PMID: 26493
-
Barbiturate and hypnosedative withdrawal by a multiple oral phenobarbital loading dose technique.
Clin Pharmacol Ther. 1981 Jul;30(1):71-6
PMID: 7237901
-
[Cumulation and elimination of phenobarbital].
Naunyn Schmiedebergs Arch Exp Pathol Pharmakol. 1962;243:479-94
PMID: 14491415
-
Interaction between phenobarbital and diphenylhydantoin in animals and in epileptic patients.
Ann N Y Acad Sci. 1971 Jul 6;179:88-107
PMID: 5285399
-
Clinical pharmacokinetics of carbamazepine.
Clin Pharmacokinet. 1978 Mar-Apr;3(2):128-43
PMID: 346287
-
Effect of activated charcoal on absorption and elimination of phenobarbitone, carbamazepine and phenylbutazone in man.
Eur J Clin Pharmacol. 1980 Jan;17(1):51-7
PMID: 7371700
-
Noncompartmental determination of the steady-state volume of distribution.
J Pharm Sci. 1979 Aug;68(8):1071-4
PMID: 480170
-
Phenobarbital and diphenylhydantoin levels in neonates with seizures.
J Pediatr. 1978 Feb;92(2):315-9
PMID: 621616